Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wingerchuk, D. M.
Right arrow Articles by Weinshenker, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wingerchuk, D. M.
Right arrow Articles by Weinshenker, B. G.
Related Collections
Right arrow Prognosis
Right arrow Devic's syndrome
Right arrowRelated Article
NEUROLOGY 2007;68:603-605
© 2007 American Academy of Neurology

A secondary progressive clinical course is uncommon in neuromyelitis optica

D. M. Wingerchuk, MD, FRCP(C), S. J. Pittock, MD, C. F. Lucchinetti, MD, V. A. Lennon, MD, PhD and B. G. Weinshenker, MD, FRCP(C)

From the Department of Neurology (D.M.W.), Mayo Clinic College of Medicine, Scottsdale, AZ; and Departments of Neurology (S.J.P., C.F.L., V.A.L., B.G.W.), Laboratory Medicine and Pathology (V.A.L., S.J.P.), and Immunology (V.A.L.), Mayo Clinic College of Medicine, Rochester, MN.

Address correspondence and reprint requests to Dr. Dean M. Wingerchuk, Department of Neurology, Mayo Clinic College of Medicine, 13400 East Shea Boulevard, Scottsdale, AZ 85259; e-mail: wingerchuk.dean{at}mayo.edu

We compared the clinical course of 96 patients with neuromyelitis optica (NMO) to multiple sclerosis (MS) natural history data. Based on the distribution of follow-up data (median 6.1 year), we estimated that 21 NMO patients would convert to a secondary progressive course, but we observed only two conversions (p = 0.00002; relative risk = 0.08). The disparate natural histories of MS and NMO suggest dissociation between relapses and clinical progression in CNS demyelinating diseases.

Disclosure: The authors report no conflicts of interest.

Received August 24, 2006. Accepted in final form October 23, 2006.


Related Article

February 20 Highlights
Neurology 2007 68: 540-541. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 NeurologyHome page
G. Giovannoni
To test or not to test: NMO-IgG and optic neuritis
Neurology, June 3, 2008; 70(23): 2192 - 2193.
[Full Text] [PDF]

Home page
 Arch OphthalmolHome page
C. C. Glisson and S. L. Galetta
Is Neuromyelitis Optica Eyeing a Distinct Path From Multiple Sclerosis?
Arch Ophthalmol, January 1, 2008; 126(1): 128 - 129.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
B. Weinshenker, S. Galetta, J. Bennett, D. Kerr, and E. M. Frohman
More on Multiple Sclerosis and Neuromyelitis Optica Reply
Arch Neurol, December 1, 2007; 64(12): 1802 - 1803.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.